Deramiocel (CAP-1002)

Name: Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Generic, brand name and therapeutic class of product
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Manufacturer: Capricor Therapeutics
Regulatory submission: Class 2 BLA resubmission submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

3 evidence topics · 3 sources

Manufacturer: Capricor Therapeutics

“Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel” (opens the source at this quote in a new tab)

Unapproved product name and drug class

“Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs)” (opens the source at this quote in a new tab)

Cellular composition

“a population of cardiac-derived stromal cells isolated from qualified donated human hearts” (opens the source at this quote in a new tab)